相似文献
1
Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).
Am J Obstet Gynecol. 2011 Dec;205(6):535.e1-5. doi: 10.1016/j.ajog.2011.06.067. Epub 2011 Jun 24.
2
Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
J Natl Cancer Inst Monogr. 2010;2010(41):181-6. doi: 10.1093/jncimonographs/lgq041.
3
Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
Am J Obstet Gynecol. 2017 Jul;217(1):59.e1-59.e12. doi: 10.1016/j.ajog.2017.03.011. Epub 2017 Mar 21.
4
From adjuvant therapy to breast cancer prevention: BCPT and STAR.
Breast J. 2001 May-Jun;7(3):144-57. doi: 10.1046/j.1524-4741.2001.007003144.x.
5
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
JAMA. 2006 Jun 21;295(23):2727-41. doi: 10.1001/jama.295.23.joc60074. Epub 2006 Jun 5.
6
What is the significance of gynecologic symptoms in the participants in the NSABP study?
Am J Obstet Gynecol. 2011 Dec;205(6):511-2. doi: 10.1016/j.ajog.2011.09.014. Epub 2011 Sep 24.
7
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Cancer Prev Res (Phila). 2010 Jun;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076. Epub 2010 Apr 19.
8
Breast cancer prevention trials.
Curr Oncol Rep. 2000 Nov;2(6):558-65. doi: 10.1007/s11912-000-0110-0.
9
The use of tamoxifen and raloxifene for the prevention of breast cancer.
Recent Results Cancer Res. 2009;181:113-9. doi: 10.1007/978-3-540-69297-3_12.
10
Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
JAMA. 2006 Jun 21;295(23):2742-51. doi: 10.1001/jama.295.23.joc60075. Epub 2006 Jun 5.
引用本文的文献
1
Does tamoxifen use increase the risk of endometrial cancer in premenopausal patients?
OBG Manag. 2023 Aug;35(8):17-21. doi: 10.12788/obgm.0297.
2
Small molecule targeted therapies for endometrial cancer: progress, challenges, and opportunities.
RSC Med Chem. 2024 Apr 11;15(6):1828-1848. doi: 10.1039/d4md00089g. eCollection 2024 Jun 19.
3
Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen.
Cancers (Basel). 2020 Jul 2;12(7):1766. doi: 10.3390/cancers12071766.
4
Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
Am J Obstet Gynecol. 2017 Jul;217(1):59.e1-59.e12. doi: 10.1016/j.ajog.2017.03.011. Epub 2017 Mar 21.
5
Gender-Specific Aspects of Lynch Syndrome and Familial Adenomatous Polyposis.
Viszeralmedizin. 2014 Apr;30(2):82-8. doi: 10.1159/000360839.
6
Investigation of women with postmenopausal uterine bleeding: clinical practice recommendations.
Perm J. 2014 Winter;18(1):55-70. doi: 10.7812/TPP/13-072. Epub 2013 Dec 30.
7
Challenging and complex decisions in the management of the BRCA mutation carrier.
J Womens Health (Larchmt). 2013 Oct;22(10):825-34. doi: 10.1089/jwh.2013.4407. Epub 2013 Aug 29.
8
How sex hormones promote skeletal muscle regeneration.
Sports Med. 2013 Nov;43(11):1089-100. doi: 10.1007/s40279-013-0081-6.
9
Raloxifene inhibits hepatitis C virus infection and replication.
FEBS Open Bio. 2012 Aug 22;2:279-83. doi: 10.1016/j.fob.2012.08.003. Print 2012.
10
Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries.
Breast Cancer Res. 2012 Jun 12;14(3):R91. doi: 10.1186/bcr3206.
本文引用的文献
1
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Cancer Prev Res (Phila). 2010 Jun;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076. Epub 2010 Apr 19.
2
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
JAMA. 2006 Jun 21;295(23):2727-41. doi: 10.1001/jama.295.23.joc60074. Epub 2006 Jun 5.
3
Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.
Am J Obstet Gynecol. 2005 Apr;192(4):1230-7; discussion 1237-9. doi: 10.1016/j.ajog.2004.12.083.
4
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61. doi: 10.1093/jnci/djh319.
5
Validation studies for models projecting the risk of invasive and total breast cancer incidence.
J Natl Cancer Inst. 1999 Sep 15;91(18):1541-8. doi: 10.1093/jnci/91.18.1541.
6
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
JAMA. 1999 Jun 16;281(23):2189-97. doi: 10.1001/jama.281.23.2189.
7
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88. doi: 10.1093/jnci/90.18.1371.
8
The induction of ovulation by tamoxifen.
J Obstet Gynaecol Br Commonw. 1973 Sep;80(9):844-7. doi: 10.1111/j.1471-0528.1973.tb11230.x.
Zotero 插件